-
1
-
-
77749289327
-
Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients
-
Franko J, Feng W, Yip L, et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg 2010;14:541-8.
-
(2010)
J Gastrointest Surg
, vol.14
, pp. 541-548
-
-
Franko, J.1
Feng, W.2
Yip, L.3
-
2
-
-
78650250772
-
Pancreatic endocrine tumors
-
Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618.
-
(2010)
Semin Oncol
, vol.37
, pp. 594-618
-
-
Oberg, K.1
-
3
-
-
84862982962
-
Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes
-
discussion 124-5
-
Cusati D, Zhang L, Harmsen WS, et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg 2012;215:117-24; discussion 124-5.
-
(2012)
J Am Coll Surg
, vol.215
, pp. 117-124
-
-
Cusati, D.1
Zhang, L.2
Harmsen, W.S.3
-
4
-
-
84857867891
-
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes
-
Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
-
(2012)
Neuroendocrinology
, vol.95
, pp. 98-119
-
-
Jensen, R.T.1
Cadiot, G.2
Brandi, M.L.3
-
5
-
-
79954463152
-
A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
-
Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011;18:127-37.
-
(2011)
Cancer Control
, vol.18
, pp. 127-137
-
-
Strosberg, J.R.1
Cheema, A.2
Kvols, L.K.3
-
6
-
-
77955195164
-
The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems
-
Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707-12.
-
(2010)
Pancreas
, vol.39
, pp. 707-712
-
-
Klimstra, D.S.1
Modlin, I.R.2
Coppola, D.3
-
7
-
-
84864353160
-
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin
-
Gu P, Wu J, Newman E, et al. Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol 2012;2012:131659.
-
(2012)
Int J Hepatol
, vol.2012
-
-
Gu, P.1
Wu, J.2
Newman, E.3
-
8
-
-
84857815160
-
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors
-
Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012;95:120-34.
-
(2012)
Neuroendocrinology
, vol.95
, pp. 120-134
-
-
Falconi, M.1
Bartsch, D.K.2
Eriksson, B.3
-
9
-
-
62049083591
-
Neuroendocrine tumors of the gastro-entero-pancreatic system
-
Massironi S, Sciola V, Peracchi M, et al. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008;14:5377-84.
-
(2008)
World J Gastroenterol
, vol.14
, pp. 5377-5384
-
-
Massironi, S.1
Sciola, V.2
Peracchi, M.3
-
10
-
-
0037269027
-
Plasma chromogranin A in patients with sporadic gastro-enteropancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1
-
Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-enteropancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003;148:39-43.
-
(2003)
Eur J Endocrinol
, vol.148
, pp. 39-43
-
-
Peracchi, M.1
Conte, D.2
Gebbia, C.3
-
11
-
-
77955179596
-
Nomenclature and classification of neuroendocrine neoplasms of the digestive system
-
Bosman FT, Carneiro F, Hruban RH, et al. eds. Lyon: International Agency for Research on Cancer (IRAC)
-
Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO classification of tumors of the digestive system. Lyon: International Agency for Research on Cancer (IRAC), 2010:13-145.
-
(2010)
WHO classification of tumors of the digestive system
, pp. 13-145
-
-
Rindi, G.1
Arnold, R.2
Bosman, F.T.3
-
12
-
-
84857838286
-
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary
-
Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-76.
-
(2012)
Neuroendocrinology
, vol.95
, pp. 157-176
-
-
Pavel, M.1
Baudin, E.2
Couvelard, A.3
-
13
-
-
29144482046
-
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization
-
Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92.
-
(2005)
Endocr Relat Cancer
, vol.12
, pp. 1083-1092
-
-
Panzuto, F.1
Nasoni, S.2
Falconi, M.3
-
14
-
-
27744575208
-
Endocrine pancreatic tumors: factors correlated with survival
-
Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16:1806-10.
-
(2005)
Ann Oncol
, vol.16
, pp. 1806-1810
-
-
Tomassetti, P.1
Campana, D.2
Piscitelli, L.3
-
15
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
-
(2011)
N Engl J Med
, vol.364
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
-
16
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13.
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
-
17
-
-
84866555560
-
Treatment of liver metastases in patients with digestive neuroendocrine tumors
-
Rossi RE, Massironi S, Spampatti MP, et al. Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg 2012;16:1981-92.
-
(2012)
J Gastrointest Surg
, vol.16
, pp. 1981-1992
-
-
Rossi, R.E.1
Massironi, S.2
Spampatti, M.P.3
-
18
-
-
55249090388
-
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors
-
Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92.
-
(2008)
Gastroenterology
, vol.135
, pp. 1469-1492
-
-
Metz, D.C.1
Jensen, R.T.2
-
19
-
-
69749123550
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations
-
Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90:167-83.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 167-183
-
-
Sundin, A.1
Vullierme, M.P.2
Kaltsas, G.3
-
20
-
-
77955211341
-
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
-
Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52.
-
(2010)
Pancreas
, vol.39
, pp. 735-752
-
-
Kulke, M.H.1
Anthony, L.B.2
Bushnell, D.L.3
-
21
-
-
3442884868
-
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
-
Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-73.
-
(2004)
Ann Oncol
, vol.15
, pp. 966-973
-
-
Oberg, K.1
Kvols, L.2
Caplin, M.3
-
22
-
-
84864979948
-
Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?
-
Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine 2012;42:3-4.
-
(2012)
Endocrine
, vol.42
, pp. 3-4
-
-
Öberg, K.1
-
23
-
-
77449132297
-
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
-
Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
-
(2010)
Endocr Relat Cancer
, vol.17
, pp. R53-73
-
-
Kwekkeboom, D.J.1
Kam, B.L.2
van Essen, M.3
-
24
-
-
69749113601
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification
-
Klöppel G, Couvelard A, Perren A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90:162-6.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 162-166
-
-
Klöppel, G.1
Couvelard, A.2
Perren, A.3
-
25
-
-
84867578755
-
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances
-
Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012;47:941-60.
-
(2012)
J Gastroenterol
, vol.47
, pp. 941-960
-
-
Ito, T.1
Igarashi, H.2
Jensen, R.T.3
-
26
-
-
60849106654
-
Pancreatic neuroendocrine tumors: the impact of surgical resection on survival
-
Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115:741-51.
-
(2009)
Cancer
, vol.115
, pp. 741-751
-
-
Hill, J.S.1
McPhee, J.T.2
McDade, T.P.3
-
27
-
-
84866422082
-
Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review
-
Harring TR, Nguyen NT, Goss JA, et al. Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol 2011;2011:154541.
-
(2011)
Int J Hepatol
, vol.2011
-
-
Harring, T.R.1
Nguyen, N.T.2
Goss, J.A.3
-
28
-
-
57449103830
-
Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas
-
Bettini R, Mantovani W, Boninsegna L, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009;41:49-55.
-
(2009)
Dig Liver Dis
, vol.41
, pp. 49-55
-
-
Bettini, R.1
Mantovani, W.2
Boninsegna, L.3
-
29
-
-
79959351349
-
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection
-
Norton JA, Harris EJ, Chen Y, et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg 2011;146:724-32.
-
(2011)
Arch Surg
, vol.146
, pp. 724-732
-
-
Norton, J.A.1
Harris, E.J.2
Chen, Y.3
-
30
-
-
79959330469
-
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor
-
Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011;150:75-82.
-
(2011)
Surgery
, vol.150
, pp. 75-82
-
-
Bettini, R.1
Partelli, S.2
Boninsegna, L.3
-
31
-
-
33646573629
-
Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE
-
discussion 663-4
-
Triponez F, Goudet P, Dosseh D, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006;30:654-62; discussion 663-4.
-
(2006)
World J Surg
, vol.30
, pp. 654-662
-
-
Triponez, F.1
Goudet, P.2
Dosseh, D.3
-
32
-
-
84878185126
-
The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors
-
Delavault P, Caplin ME, Liyange N, et al. The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors. J Clin Oncol 2012;30:abstr TPS4153.
-
(2012)
J Clin Oncol
, vol.30
-
-
Delavault, P.1
Caplin, M.E.2
Liyange, N.3
-
33
-
-
53849134827
-
Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
-
Grozinsky-Glasberg S, Shimon I, Korbonits M, et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008;15:701-20.
-
(2008)
Endocr Relat Cancer
, vol.15
, pp. 701-720
-
-
Grozinsky-Glasberg, S.1
Shimon, I.2
Korbonits, M.3
-
34
-
-
77956338644
-
Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors
-
Massironi S, Conte D, Sciola V, et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am J Gastroenterol 2010;105:2072-8.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 2072-2078
-
-
Massironi, S.1
Conte, D.2
Sciola, V.3
-
35
-
-
84862856431
-
Antitumor effects of somatostatin analogs in neuroendocrine tumors
-
Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012;17:747-55.
-
(2012)
Oncologist
, vol.17
, pp. 747-755
-
-
Sidéris, L.1
Dubé, P.2
Rinke, A.3
-
36
-
-
77950194045
-
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
-
Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res 2010;29:19.
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 19
-
-
Appetecchia, M.1
Baldelli, R.2
-
38
-
-
77954556448
-
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors
-
Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:2963-70.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 2963-2970
-
-
Strosberg, J.1
Kvols, L.2
-
39
-
-
70350442637
-
Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group
-
Rinke A, Müller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4656-4663
-
-
Rinke, A.1
Müller, H.H.2
Schade-Brittinger, C.3
-
41
-
-
33846848120
-
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
-
Butturini G, Bettini R, Missiaglia E, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213-21.
-
(2006)
Endocr Relat Cancer
, vol.13
, pp. 1213-1221
-
-
Butturini, G.1
Bettini, R.2
Missiaglia, E.3
-
42
-
-
84862889164
-
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses
-
Ferolla P, Faggiano A, Grimaldi F, et al. Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest 2012;35:326-31.
-
(2012)
J Endocrinol Invest
, vol.35
, pp. 326-331
-
-
Ferolla, P.1
Faggiano, A.2
Grimaldi, F.3
-
43
-
-
82355175321
-
Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
-
Ludlam WH, Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 2011;28:825-41.
-
(2011)
Adv Ther
, vol.28
, pp. 825-841
-
-
Ludlam, W.H.1
Anthony, L.2
-
44
-
-
4344699187
-
High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours
-
Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-12.
-
(2004)
Eur J Endocrinol
, vol.151
, pp. 107-112
-
-
Welin, S.V.1
Janson, E.T.2
Sundin, A.3
-
45
-
-
69749110763
-
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy
-
Oberg K, Ferone D, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. Neuroendocrinology 2009;90:209-13.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 209-213
-
-
Oberg, K.1
Ferone, D.2
Kaltsas, G.3
-
47
-
-
58849093671
-
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
-
Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 338-345
-
-
Kulke, M.H.1
Hornick, J.L.2
Frauenhoffer, C.3
-
48
-
-
33947240452
-
Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours
-
Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:131-44.
-
(2007)
Best Pract Res Clin Endocrinol Metab
, vol.21
, pp. 131-144
-
-
Toumpanakis, C.1
Meyer, T.2
Caplin, M.E.3
-
49
-
-
14644413806
-
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
-
Kouvaraki MA, Ajani JA, HoffP, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
-
(2004)
J Clin Oncol
, vol.22
, pp. 4762-4771
-
-
Kouvaraki, M.A.1
Ajani, J.A.2
Hoff, P.3
-
50
-
-
78650993549
-
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
-
Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75.
-
(2011)
Cancer
, vol.117
, pp. 268-275
-
-
Strosberg, J.R.1
Fine, R.L.2
Choi, J.3
-
51
-
-
67651122899
-
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors
-
Maire F, Hammel P, Faivre S, et al. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. Neuroendocrinology 2009;90:67-72.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 67-72
-
-
Maire, F.1
Hammel, P.2
Faivre, S.3
-
52
-
-
83255171192
-
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
-
Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012;61:6-32.
-
(2012)
Gut
, vol.61
, pp. 6-32
-
-
Ramage, J.K.1
Ahmed, A.2
Ardill, J.3
-
53
-
-
77954658554
-
ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors
-
Kos-Kudla B, O, Toole D, Falconi M, et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 2010;91:341-50.
-
(2010)
Neuroendocrinology
, vol.91
, pp. 341-350
-
-
Kos-Kudla, B.O.1
Toole, D.2
Falconi, M.3
-
54
-
-
79952279828
-
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
-
Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203.
-
(2011)
Science
, vol.331
, pp. 1199-1203
-
-
Jiao, Y.1
Shi, C.2
Edil, B.H.3
-
55
-
-
79851493429
-
Promising advances in the treatment of malignant pancreatic endocrine tumors
-
Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-5.
-
(2011)
N Engl J Med
, vol.364
, pp. 564-565
-
-
Jensen, R.T.1
Delle Fave, G.2
-
56
-
-
74949122343
-
Pancreatic endocrine tumors: expression profiling evidences a role for AKTmTOR pathway
-
Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKTmTOR pathway. J Clin Oncol 2010;28:245-55.
-
(2010)
J Clin Oncol
, vol.28
, pp. 245-255
-
-
Missiaglia, E.1
Dalai, I.2
Barbi, S.3
-
57
-
-
52049125970
-
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study
-
Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4311-4318
-
-
Yao, J.C.1
Phan, A.T.2
Chang, D.Z.3
-
58
-
-
73949088959
-
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
-
Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
-
(2010)
J Clin Oncol
, vol.28
, pp. 69-76
-
-
Yao, J.C.1
Lombard-Bohas, C.2
Baudin, E.3
-
60
-
-
33750510023
-
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
-
Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
-
(2006)
Br J Cancer
, vol.95
, pp. 1148-1154
-
-
Duran, I.1
Kortmansky, J.2
Singh, D.3
-
61
-
-
79953308250
-
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Hobday T, Castellano D, et al. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer Metastasis Rev 2011;30:19-26.
-
(2011)
Cancer Metastasis Rev
, vol.30
, pp. 19-26
-
-
Raymond, E.1
Hobday, T.2
Castellano, D.3
-
62
-
-
49149114782
-
Activity of sunitinib in patients with advanced neuroendocrine tumors
-
Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-10.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3403-3410
-
-
Kulke, M.H.1
Lenz, H.J.2
Meropol, N.J.3
-
63
-
-
84884817266
-
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
-
Ito T, Okusaka T, Nishida T, et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013;31:1265-74.
-
(2013)
Invest New Drugs
, vol.31
, pp. 1265-1274
-
-
Ito, T.1
Okusaka, T.2
Nishida, T.3
-
64
-
-
84874112933
-
Treatment of gastroenteropancreatic neuroendocrine tumors with Peptide receptor radionuclide therapy
-
van Vliet EI, Teunissen JJ, Kam BL, et al. Treatment of gastroenteropancreatic neuroendocrine tumors with Peptide receptor radionuclide therapy. Neuroendocrinology 2013;97:74-85.
-
(2013)
Neuroendocrinology
, vol.97
, pp. 74-85
-
-
van Vliet, E.I.1
Teunissen, J.J.2
Kam, B.L.3
-
65
-
-
43749091955
-
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival
-
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2124-2130
-
-
Kwekkeboom, D.J.1
de Herder, W.W.2
Kam, B.L.3
-
66
-
-
21044451724
-
Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
-
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2754-2762
-
-
Kwekkeboom, D.J.1
Teunissen, J.J.2
Bakker, W.H.3
-
67
-
-
6044233448
-
Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors
-
Ruszniewski P, O, Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 2004;80:74-8.
-
(2004)
Neuroendocrinology
, vol.80
, pp. 74-78
-
-
Ruszniewski, P.O.1
Toole, D.2
-
68
-
-
24044512977
-
Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques
-
Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005;28:409-21.
-
(2005)
Cardiovasc Intervent Radiol
, vol.28
, pp. 409-421
-
-
Atwell, T.D.1
Charboneau, J.W.2
Que, F.G.3
-
69
-
-
66149150091
-
Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours
-
Srirajaskanthan R, Toumpanakis C, Meyer T, et al. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. Aliment Pharmacol Ther 2009;29:1143-54.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 1143-1154
-
-
Srirajaskanthan, R.1
Toumpanakis, C.2
Meyer, T.3
-
71
-
-
26844447505
-
Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours
-
O, Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585-94.
-
(2005)
Best Pract Res Clin Gastroenterol
, vol.19
, pp. 585-594
-
-
Toole, O.D.1
Ruszniewski, P.2
-
72
-
-
84861591919
-
Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications
-
Lewis MA, Jaramillo S, Roberts L, et al. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012;17:725-31.
-
(2012)
Oncologist
, vol.17
, pp. 725-731
-
-
Lewis, M.A.1
Jaramillo, S.2
Roberts, L.3
-
73
-
-
69249165991
-
Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation
-
Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 2009;72:517-28.
-
(2009)
Eur J Radiol
, vol.72
, pp. 517-528
-
-
Vogl, T.J.1
Naguib, N.N.2
Zangos, S.3
-
74
-
-
84867583207
-
Radioembolization in the treatment of neuroendocrine tumor metastases to the liver
-
Vyleta M, Coldwell D. Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011;2011:785315.
-
(2011)
Int J Hepatol
, vol.2011
-
-
Vyleta, M.1
Coldwell, D.2
-
75
-
-
77951478799
-
Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies
-
Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010;16:163-75.
-
(2010)
Cancer J
, vol.16
, pp. 163-175
-
-
Kennedy, A.S.1
Salem, R.2
-
76
-
-
34548255524
-
Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?
-
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 2007;47:460-6.
-
(2007)
J Hepatol
, vol.47
, pp. 460-466
-
-
Mazzaferro, V.1
Pulvirenti, A.2
Coppa, J.3
|